#153397

Anti-MUC1 [C789]

Cat. #153397

Anti-MUC1 [C789]

Cat. #: 153397

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: MUC1

Class: Monoclonal

Application: IHC

Reactivity: Human ; Xenopus laevis

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Mike Price

Institute: University of Nottingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-MUC1 [C789]
  • Alternate name: CD227; KL6; Mucin 1; PEMT
  • Clone: C789
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 122 kDa
  • Reactivity: Human ; Xenopus laevis
  • Host: Mouse
  • Application: IHC
  • Description: MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1.
  • Immunogen: need access to this paper to answer this - https://www.ncbi.nlm.nih.gov/pubmed/?term=fine+specificity+of+antibody+recognition+of+carcinoma-associated+epithelial+musincs

Target Details

  • Target: MUC1
  • Molecular weight: 122 kDa
  • Target background: MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1.

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -80° C
  • Shipping conditions: Shipping at 4° C

References

  • Croce et al. 1997. Anticancer Res. 17(6D):4287-92. PMID: 9494522.
  • Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study.